WGS
Get informed when a big investor buys or sells
+ FollowOvervalued by 258.6% based on the discounted cash flow analysis.
| Market cap | $3.02 Billion |
|---|---|
| Enterprise Value | $3.12 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.73 |
| Beta | 2.01 |
| Outstanding Shares | 29,710,139 |
| P/E Ratio | -27.77 |
|---|---|
| PEG | 10.52 |
| Price to Sales | 5.9 |
| Price to Book Ratio | 11.06 |
| Enterprise Value to Revenue | 6.87 |
| Enterprise Value to EBIT | -46.35 |
| Enterprise Value to Net Income | -30 |
| Total Debt to Enterprise | 0.05 |
| Debt to Equity | 0.69 |
No data
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.3541▼ 11.72% |
|---|---|
| Total Calls | 838,400▲ 101.83% |
| Total Puts | 296,900▲ 51.63% |
Holdings and activity of institutional investors.
| Ownership % | 106.89%▲ 0.36% |
|---|---|
| Total Invested | $2.18B▲ 8.58% |
| Investors Holding | 240▼ 13.00% |
No data
Sema4 is a patient-centered health intelligence company dedicated to advancing healthcare through data-driven insights. Sema4 is transforming healthcare by applying AI and machine learning to multidimensional, longitudinal clinical and g...